ALCON's OPHTHALMIC STEROID/ANTIBIOTIC TOBRADEX
ALCON's OPHTHALMIC STEROID/ANTIBIOTIC TOBRADEX is a "significant improvement in combination therapy," the firm maintains in a recent introductory trade letter. TobraDex, a combination of tobramycin and dexamethasone, was approved by FDA on Aug. 19 after approximately three-and-a-half years of review. Alcon already has a leading product in the steroid/antibiotic ophthalmic market, Maxitrol (neomycin sulfate, polymyxin B sulfate and dexamethasone). Alcon claims that Maxitrol is the leader in the $ 30 mil. category. In a promotional fact sheet on TobraDex, Alcon asserts that the product has "unsurpassed antibiotic spectrum, . . . optimum anti-inflammatory activity [and is] less sensitizing than combinations with neomycin." Alcon began shipping TobraDex Aug. 24. The firm's price to wholesalers is $ 9 for a 5 ml dispenser and $ 108 for a dozen dispensers. Approved labeling states that "TobraDex opthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists." Ocular steriods, labeling continues, "are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies." Alcon also markets tobramycin as a single ingredient product, under the brand name Tobrex, for external eye infections. The firm licenses rights to ophthalmic uses of the antibiotic from Lilly. Alcon noted that the tobramycin patent expires next year and that the firm is exploring options for ensuring exclusivity of the new combination product.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth